

## AstraZeneca Development Pipeline 29 January 2009

### Line Extensions

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Cardiovascular</b>					
<i>Atacand</i>	angiotensin II antagonist	diabetic retinopathy	III	Published*	Published*
<i>Atacand Plus</i>	angiotensin II antagonist/thiazide diuretic	32/12.5 mg, 32/25 mg for hypertension	III	Filed	
<i>Crestor</i>	statin	outcomes in subjects with elevated CRP	III	2Q 2009	2Q 2009
<i>Onglyza/metformin FDC<sup>#</sup></i>	DPP-4 inhibitor + biguanide FDC	diabetes	III	2H 2010	4Q 2009
<i>Dapagliflozin/metformin FDC<sup>#</sup></i>	SGLT2 inhibitor + biguanide FDC	diabetes	III	2011	2011
<b>Gastrointestinal</b>					
<i>Nexium</i>	proton pump inhibitor	peptic ulcer bleeding	III	Filed	Filed
<i>Nexium low dose aspirin combination</i>	proton pump inhibitor	low dose aspirin associated peptic ulcer	III	3Q 2009	2Q 2009
<i>Nexium</i>	proton pump inhibitor	extra-oesophageal reflux disease	II	3Q 2009*	3Q 2009*
<b>Neuroscience</b>					
<i>Seroquel</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	bipolar maintenance	III	Filed	Launched
<i>Seroquel</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	bipolar depression	III	Approved	Launched
<i>Seroquel XR</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	major depressive disorder	III	Filed	Filed
<i>Seroquel XR</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	bipolar mania	III	Approved	Approved
<i>Seroquel XR</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	bipolar depression	III	Approved	Approved
<i>Seroquel XR</i>	D <sub>2</sub> /5HT <sub>2</sub> antagonist	generalised anxiety disorder	III	Filed	Filed
<b>Oncology &amp; Infection</b>					
<i>FluMist</i>	live, attenuated, intranasal influenza virus vaccine	influenza	III	Filed	Launched
<i>Iressa</i>	EGFR tyrosine kinase inhibitor	NSCLC	III	Filed	
<i>Zactima</i>	VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity	medullary thyroid cancer	III	2H 2010	4Q 2009
<i>Motavizumab</i>	humanized MAb binding to RSV F protein	early and late treatment of RSV in paed >1 yr	II		
<i>Faslodex</i>	oestrogen receptor antagonist	first line advanced breast cancer	III		
<i>Faslodex</i>	oestrogen receptor antagonist	adjuvant	III		

\*Publication only

<sup>#</sup>Partnered product

**Line Extensions (continued)**

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Respiratory &amp; Inflammation</b>					
<i>Symbicort</i> pMDI	inhaled steroid/fast onset, long-acting $\beta_2$ agonist	asthma	III	Filed	Launched*
<i>Symbicort</i> pMDI	inhaled steroid/fast onset, long-acting $\beta_2$ agonist	COPD	III	Filed	Filed
Unit Dose Budesonide **	inhaled steroid	asthma	III		

\*US approval based on 12 years and above

\*\*Partnered product. Subject to review under the Hart Scott Rodino Act

## NCEs

### Phase III/Registration

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Cardiovascular</b>					
<i>Onglyza</i> <sup>#</sup>	DPP-4 inhibitor	diabetes	III	Filed	Filed
<i>Brilinta</i> (AZD6140)	ADP receptor antagonist	arterial thrombosis	III	4Q 2009	4Q 2009
<i>Crestor/TriLipix</i> <sup>#</sup>	statin + fibrate fixed combination	dyslipidaemia	III		3Q 2009
Dapagliflozin <sup>#</sup>	SGLT2 inhibitor	diabetes	III	2H 2010	2H 2010
<b>Neuroscience</b>					
PN400 <sup>#</sup>	naproxen + esomeprazole	signs and symptoms of OA, RA and AS	III	4Q 2009	Mid 2009
<b>Oncology &amp; Infection</b>					
Motavizumab	humanized MAb binding to RSV F protein	RSV prevention	III	TBD	Filed
<i>Zactima</i>	VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity	NSCLC	III	2Q 2009	2Q 2009
<i>Recentin</i>	VEGFR tyrosine kinase inhibitor	CRC	III	2H 2010	2H 2010
<i>Recentin</i>	VEGFR tyrosine kinase inhibitor	recurrent glioblastoma	III	2H 2010	2H 2010
ZD4054	endothelin A receptor antagonist	hormone resistant prostate cancer	III	2011	2011

<sup>#</sup>Partnered product

## NCEs

### Phases I and II

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Cardiovascular</b>					
AZD0837	direct thrombin inhibitor	thrombosis	II	2012	2012
AZD1305	antiarrhythmic	arrhythmias	II		
AZD6370	GK activator	diabetes	II		
AZD1656	GK activator	diabetes/obesity	II		
AZD6482	PI3K-beta inhibitor	thrombosis	I		
AZD4017	11BHS D inhibitor	diabetes/obesity	I		
<b>Gastrointestinal</b>					
AZD3355	inhibitor of transient lower oesophageal sphincter relaxations (TLESR)	GERD	II	2011	2011
AZD2066	metabotropic glutamate receptor 5 antagonist	GERD	I		
AZD1386	vanilloid receptor antagonist	GERD	I		
<b>Neuroscience</b>					
AZD3480 <sup>#</sup>	neuronal nicotinic receptor agonist	Alzheimer's disease	II		
AZD6765	NMDA receptor antagonist	depression	II	2012	2012
AZD1940	CB1 receptor agonist	nociceptive and neuropathic pain	II		
AZD1386	vanilloid receptor antagonist	chronic nociceptive pain	II		
AZD2624	NK receptor antagonist	schizophrenia	II		
AZD2327	enkephalinergic receptor modulator	anxiety and depression	II		
AZD7325	GABA receptor subtype partial agonist	anxiety	II	2013	2012
AZD5904	myeloperoxidase (MPO) inhibitor	multiple sclerosis	I		
AZD3241	myeloperoxidase (MPO) inhibitor	Parkinson's disease	I		
AZD2066	metabotropic glutamate receptor 5 antagonist	chronic neuropathic pain	I		
AZD6280	GABA receptor subtype partial agonist	anxiety	I		
TC-5619 <sup>#</sup>	neuronal nicotinic receptor agonist	cognitive disorders in schizophrenia	I		
AZD8529	glutamatergic modulator	schizophrenia	I		
AZD2516	metabotropic glutamate receptor 5 antagonist	chronic neuropathic pain	I		
AZD1446	neuronal nicotinic receptor agonist	Alzheimer's disease	I		
AZD7268	enkephalinergic receptor modulator	depression/anxiety	I		

<sup>#</sup>Partnered product

## NCEs

### Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Oncology &amp; Infection</b>					
<i>Recentin</i>	VEGFR tyrosine kinase inhibitor	NSCLC	II	2013	2013
<i>CytoFab</i> <sup>#</sup>	anti-TNF-alpha polyclonal antibody	severe sepsis	II		
AZD6244 <sup>#</sup> (ARRY-142886)	MEK inhibitor	solid tumours	II	2014	2014
AZD2281	PARP inhibitor	breast/ovarian cancer	II	2012	2012
EBV vaccine <sup>#</sup>	Epstein-Barr virus vaccine	post-transplant proliferative disease	II		
AZD0530	SRC kinase inhibitor	solid tumours and haematological malignancies	II		
AZD4877	cell cycle agent	haematological malignancies	II		
AZD7295	NS 5a inhibitor	hepatitis C	II		
AZD1152	aurora kinase inhibitor	haematological malignancies	II	2011	2011
AZD4769	EGFR tyrosine kinase inhibitor	solid tumours	I		
AZD8931	erbB kinase inhibitor	solid tumours	I		
AZD7762	CHK1 kinase Inhibitor	solid tumours	I		
AZD8330 <sup>#</sup> (ARRY-424704)	MEK inhibitor	solid tumours	I		
CAT-8015	recombinant immunotoxin	haematological malignancies	I		
MEDI-534	RSV/PIV-3 vaccine	intranasal immunisation	I		
MEDI-538 <sup>#</sup>	CD19 B cells	leukaemia/lymphoma	I		
MEDI-560	PIV-3 vaccine	intranasal immunisation	I		
MEDI-566	pandemic influenza virus vaccine	pandemic influenza vaccine	I		
AZD9639 (MEDI-564) <sup>#</sup>	RSV F protein inhibitor	RSV treatment	I		
CMV Vaccine	CMV vaccine	cytomegalovirus	I		
MEDI-557	YTE – extended half-life RSV MAb	RSV prophylaxis	I		
AZD8055	TOR kinase inhibitor	range of tumours	I		
AZD6918	TRK inhibitor	solid tumours	I		
MEDI-559	RSV vaccine	RSV treatment	I		

<sup>#</sup>Partnered product

## NCEs

### Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
<b>Respiratory &amp; Inflammation</b>					
AZD9056	ion channel blocker (P2X7)	rheumatoid arthritis	II	2012	2012
AZD5672	chemokine receptor antagonist (CCR5)	rheumatoid arthritis	II	2012	2012
AZD1981	CRTh2 receptor antagonist	asthma/COPD	II		
MEDI-528	anti-IL-9 antibody	asthma	II		
CAT-354	anti-IL-13 antibody	asthma	II		
AZD9668	neutrophil elastase inhibitor	COPD	II		
AZD1236	matrix metallo-proteinase inhibitor	COPD	II		
AZD3199	iLABA	asthma/COPD	II		
MEDI-563	anti-IL-5R antibody	asthma	II		
MEDI-545	anti-IFN-alpha antibody	SLE, myositis	II		
Pneumococcal vaccine <sup>#</sup>	pneumococcal vaccine	Streptococcus pneumoniae	I		
CAM-3001	anti-GM-CSFR	rheumatoid arthritis	I		
AZD8848		asthma	I		
AZD8566	CCR5	rheumatoid arthritis	I		
AZD8075	CRTh2 antagonist	asthma/COPD	I		
AZD5985	CRTh2 antagonist	asthma/COPD	I		

<sup>#</sup>Partnered product

## AstraZeneca Development Pipeline

### Discontinued Projects vs 31 July 2008 HY

#### Cardiovascular & Gastrointestinal

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD1175	diabetes/obesity
NCE	AZD2207	diabetes/obesity
LCM	Crestor outcomes end stage renal disease*	renal disease

#### Neuroscience

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD3480	cognitive disorder in schizophrenia
NCE	AZD0328	Alzheimer's disease
NCE	AZD1704	analgesia

#### Oncology & Infection

NCE/Line Extension	Compound	Area Under Investigation
NCE	MEDI-561 (IPI-504)	GIST
NCE	MEDI-561 (IPI-504)	solid tumours
NCE	IPI-493	solid tumours
NCE	AZD4877	solid tumours
NCE	AZD1152	solid tumours
NCE	AZD2836	hepatitis C

#### Respiratory & Inflammation

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD4818	COPD

\* Will proceed to publication

#### Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

Abbreviations:

MAA – Marketing Authorisation Application (Europe).

NDA – New Drug Application/Biologics Licensing Application (USA).